Video
Individuals With Chronic Lymphocytic Leukemia Benefit More From iFCR Therapy Than Older Individuals
Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how the results of a longer term study differ for individuals who were younger with chronic lymphocytic leukemia as opposed to those who are older.
In a Pharmacy Times® Interview, Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses his oral presentation at ASH 2021 of the Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia (CLL).
He discussed how the results of a longer term study differ for individuals who were younger as opposed to those who are older.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
